# Synthesis of Novel Bidentate P-Chiral Diaminophosphine Oxide Preligands: Application to Pd-Catalyzed Asymmetric Allylic Substitution Reactions

Teisuke HARADA, Tetsuhiro NEMOTO, Long JIN, and Yasumasa HAMADA\*

*Graduate School of Pharmaceutical Sciences, Chiba University; 1–33 Yayoi-cho, Inage-ku, Chiba 263–8522, Japan.* Received November 27, 2010; accepted December 15, 2010; published online December 15, 2010

We developed a novel (S)-L-phenylalanine derived-bidentate chiral diaminophosphine oxide (DIAPHOX) preligand  $(S,S_p)$ -9b, which was successfully applied to Pd-catalyzed asymmetric allylic alkylation and amination. Using the Pd- $(S,S_p)$ -9b catalyst system, asymmetric allylic alkylation and amination proceeded very smoothly, affording the corresponding products in excellent yield with high enantiomeric excess. It is noteworthy that both enantiomers were accessible with high enantiomeric purity using the structurally related DIAPHOX preligands  $(S,S_p)$ -9b and a monodentate chiral diaminophosphine oxide preligand  $(S,R_p)$ -10a, both of which can be prepared from a single chiral source, (S)-L-phenylalanine.

Key word chiral diaminophosphine oxide; asymmetric allylic substitution; palladium; asymmetric catalysis; preligand

Pd-catalyzed asymmetric allylic substitutions have received considerable attention as useful asymmetric carboncarbon bond or carbon-heteroatom bond-forming reactions, where racemic or achiral allylic substrates can be converted into optically active products in the presence of a palladium-chiral ligand complex. Extensive efforts have been directed towards the development of effective chiral ligands for this transformation.<sup>1-3</sup> Over the past two decades, we have focused on the development of chiral phosphorus ligands for transition metal-catalyzed asymmetric allylic substitutions.<sup>4–7)</sup> In 2004, we developed a new class of chiral phosphorus ligands: aspartic acid-derived P-chiral diaminophosphine oxide 1 and its derivatives (DIAPHOXs). These pentavalent phosphorus compounds, preligands, are activated in situ by N,O-bis(trimethysilyl)acetamide (BSA) induced P(V)—P(III) tautomerization to afford trivalent phosphorus species such as 2, which function as actual ligands (Chart 1). These preligands have been successfully applied to Pd- and Ir-catalyzed asymmetric allylic substitution reactions.<sup>8-22)</sup> Detailed investigations into the reaction mechanism using a Pd-catalyzed asymmetric allylic alkylation of 1,3-diphenylallyl acetate with dimethyl malonate revealed that complex 3 [Pd-2 (1:2) complex] was the active catalyst.<sup>9</sup> With this result in hand, we became interested in the development of bidentate P-chiral diaminophosphine oxide preligands with an achiral diphenylphosphine moiety as the second coordinating group. Herein, we report the design and synthesis of novel phenylalanine derived-bidentate P-chiral diaminophosphine oxide preligands that can be applied to Pd-catalyzed asymmetric allylic alkylation and amination.

# **Results and Discussion**

Our ligand design is outlined in Fig. 1. The original DI-APHOX preligands involve an arylmethylene unit on a nitrogen atom adjacent to the phosphorus atom, which is introduced by reduction of the corresponding benzamide. The commercial availability of 2-diphenylphosphinobenzoic acid led us to introduce a diphenylphosphine moiety into the DI-APHOX framework by reducing the corresponding benzamide prepared from this reagent. Thus, we set up the methylene-tethered P-chiral diaminophosphine oxide–triphenylphosphine hybrids as our target ligands. (*S*)-Phenylalanine was selected as the starting material to prepare both diastereomers of chiral ligands originating from the chirality of the phosphorus atom.<sup>23)</sup>

Our ligand synthesis started with commercially available N-Z-(S)-phenylalanine 4 (Chart 2). First, 4 was reacted with aniline using 1-ethyl-3-(3-diethylaminopropyl)-carbodiimide hydrochloride (EDC) as a coupling reagent to give the corresponding anilide, which was converted into the known primary amine derivative 5 through reductive removal of the Z group (94% yield, 2 steps). Subsequent condensation of 5 with 2-diphenylphosphinobenzoic acid using 1 eq of dicyclo-



Chart 1. BSA-Induced P(V)—P(III) Tautomerization of DIAPHOXs and the Active Catalyst Structure of the Asymmetric Allylic Substitution Using the Pd-DIAPHOX Catalyst System



Fig. 1. Design of Bidentate P-Chiral Diaminophosphine Oxide Preligands



Reagents and conditions: (a) aniline, EDC, DMF, rt. (b) Pd-C, H<sub>2</sub>, DMF–2-propanol, rt. (c) DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, rt. (d) NaBH<sub>4</sub>, I<sub>2</sub>, THF, reflux. (e) PCl<sub>3</sub>, NEt<sub>3</sub>, toluene, -78 °C to rt, then H<sub>2</sub>O.

Chart 2. Ligand Synthesis

hexylcarbodiimide (DCC) and 10 mol% of *N*,*N*-dimethylaminopyridine (DMAP) provided **6** in 98% yield.<sup>24)</sup> Reduction of the amide groups of **6** using *in situ*-generated BH<sub>3</sub> afforded a mixture of the desired diamine **8** (63% yield) and the monoamine **7** (25% yield). Recovered **7** was successfully transformed into **8** in 76% yield by treating with BH<sub>3</sub> again (total yield of **8**: 82%). Finally, the obtained diamine **8** was reacted with phosphorous trichloride in the presence of NEt<sub>3</sub>. After work-up by the addition of water, the obtained residue was purified by flash column chromatography to give the target compounds (*S*,*R*<sub>P</sub>)-**9a** and (*S*,*S*<sub>P</sub>)-**9b** in 27% yield and 55% yield, respectively.<sup>25</sup>

We next used the bidentate P-chiral diaminophosphine oxides  $(S,R_p)$ -9a and  $(S,S_p)$ -9b as chiral phosphorus ligands for a Pd-catalyzed asymmetric allylic alkylation of 1,3-diphenylallyl acetate 11 with dimethyl malonate (Table 1). We first examined the reaction using the corresponding monodentatetype DIAPHOX  $(S, R_p)$ -10 $a^{16}$  and  $(S, S_p)$ -10 $b^{16}$  as the control experiments. Using 1 mol% of  $[\eta^3-C_3H_5PdCl]_2$  and 4 mol% of  $(S,R_P)$ -10a (Pd/ligand=1/2),<sup>26)</sup> the reaction proceeded smoothly at 4 °C to provide (S)-12 in 99% yield with 95% ee (entry 1). Using  $(S, S_p)$ -10b, however, the same reaction proceeded very sluggishly, affording the product with an opposite stereochemistry in only 35% yield, even after 96 h (entry 2). In striking contrast, chiral Pd catalysts prepared using  $(S,R_{\rm p})$ -9a or  $(S,S_{\rm p})$ -9b effectively promoted the reaction. In particular, when the reaction was performed using 1 mol% of  $[\eta^3 - C_3 H_5 PdCl]_2$  and 2 mol% of  $(S, S_P) - 9b$  (Pd/ligand = 1/1) at 4 °C, (R)-12 was obtained in 99% yield with 93% ee (entry 4). Conventionally, unnatural (R)-D-amino acid-derived DI-APHOX preligands, such as  $(R, S_{\rm P})$ -10a, were essential to obtain products with an opposite stereochemistry to that obtained with DIAPHOXs bearing  $(S, R_{\rm P})$  configurations (entry 5). It is noteworthy that both enantiomers were accessible with high enantiomeric purity using the structurally related DIAPHOX preligands derived from a single chiral source, (S)-L-phenylalanine. The Pd- $(S, S_P)$ -9b catalyst system was also applicable to asymmetric allylic amination. When benzylamine and morpholine were utilized as nucleophiles, the

#### Table 1. Pd-Catalyzed Asymmetric Allylic Alkylation



Chart 3. Pd-Catalyzed Asymmetric Allylic Amination

corresponding products (S)-13 and (S)-14 were obtained in 96% yield with 85% ee and in 98% yield with 80% ee, respectively (Chart 3).

In conclusion, we developed a novel phenylalanine derived-bidentate chiral diaminophosphine oxide preligand  $(S,S_p)$ -9b, which was successfully applied to Pd-catalyzed asymmetric allylic alkylation and amination. Both enantiomers were accessible in a highly enantioselective manner using  $(S,S_p)$ -9b and  $(S,R_p)$ -10a, both of which can be prepared from a single chiral source. Detailed mechanistic investigations into the present catalyst system, as well as studies on the application of bidentate-type DIAPHOX preligands to other catalytic asymmetric reactions, are in progress.

## Experimental

**General** Infrared (IR) spectra were recorded on a JASCO Fourier transform (FT)/IR 230 Fourier transform infrared spectrophotometer, equipped with ATR (Smiths Detection, DuraSample IR II, Canada). NMR spectra were recorded on a JEOL ecp 400 spectrometer, operating at 400 MHz for <sup>1</sup>H-NMR, 100 MHz for <sup>13</sup>C-NMR, and 160 MHz for <sup>31</sup>P-NMR. Optical rotations were measured on a JASCO P-1020 polarimeter. Electrospray ionization (ESI) mass spectra were measured on JEOL AccuTOF LC-plus JMS T100LP. The enantiomeric excess was determined by HPLC analysis. HPLC was performed on JASCO HPLC systems consisting of the following: pump, PU-980; detector, UV-970, measured at 254 nm. Reactions were carried out in dry solvent. Other reagents were purified by the usual methods.

Preparation of Bidentate P-Chiral Diaminophosphine Oxide  $(S,R_p)$ -9a and  $(S,S_p)$ -9b. Compound 6 To a stirred solution of 5 (200 mg, 0.832 mmol), which was prepared using the reported method (94% yield, 2 steps from 4),<sup>16</sup> 2-diphenylphosphinobenzoic acid (280.4 mg, 0.915 mmol)

and DMAP (111.8 mg, 0.915 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4.1 ml) at room temperature was added DCC (206.3 mg, 1.00 mmol). The resulting mixture was kept stirring at the same temperature. After 24 h, the mixture was filtered through a short pad of celite, and the filtrate was evaporated under reduced pressure. The crude residue was purified by flash column chromatography (SiO<sub>2</sub>, hexane/AcOEt=10/1) to give 6 (430.9 mg, 98% yield) as white solids. IR (ATR) v 3264, 3058, 1678, 1618, 1584, 1530, 1496, 1444, 1434, 1389, 1299, 1251, 738, 692 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>2</sub>)  $\delta$ : 2.91 (dd, J=7.6, 14.4 Hz, 1H), 3.20 (dd, J=6.8, 14.4 Hz, 1H), 4.84 (ddd, J=6.8, 7.2, 7.6 Hz, 1H), 6.33 (d, J=7.2 Hz, 1H), 6.97-7.01 (m, 1H), 7.06-7.11 (m, 2H), 7.21-7.38 (m, 18H), 7.40-7.44 (m, 1H), 7.48-7.50 (m, 2H), 8.44 (s, 1H); <sup>13</sup>C-NMR  $(CDCl_3)$   $\delta$ : 37.5, 55.9, 120.2 (2C), 124.3, 127.0, 127.8 (d, J=5.8 Hz), 128.7 (d, J=7.2 Hz) (2C), 128.7 (2C), 128.8 (2C), 128.9 (d, J=7.3 Hz) (2C), 129.2 (2C), 128.8—129.2 (m, 3C), 130.6, 133.6 (d, J=13.0 Hz) (2C), 133,8 (d, J=13.4 Hz) (2C), 134.3, 135.5-138.4 (m, 3C), 136.5, 137.6, 140.5, 168.6, 169.4; <sup>31</sup>P-NMR (CDCl<sub>3</sub>)  $\delta$ : -10.7; ESI-high resolution (HR)-MS. Calcd for  $C_{34}H_{29}N_2NaO_2P$  (M+Na<sup>+</sup>): 551.1864. Found: 551.1858;  $[\alpha]_D^{23}$  -48.0  $(c=2.41, \text{CHCl}_3).$ 

Compound 8 To a stirred suspension of 6 (427.3 mg, 0.81 mmol) and NaBH<sub>4</sub> (184.7 mg, 4.86 mmol) in tetrahydrofuran (THF) (4.1 ml) was added a THF solution of I2 (308.4 mg, 2.43 mmol in 4 ml of THF) at 0 °C over 3 min. The reaction mixture was refluxed for 48 h, cooled to 0 °C, and then 1 N HCl was added to the reaction mixture. After refluxing for 2 h, the reaction mixture was neutralized using 1 N NaOH. The organic layer was separated and aqueous layer was extracted with AcOEt. The combined organic layers were washed with water, brine, and dried over Na2SO4. After concentration under reduced pressure, the residue was purified by flash column chromatography (SiO2, hexane/AcOEt=10/1 to 2/1) to give diamine 8 (255.0 mg, 63% yield) and monoamine 7 (102.9 mg, 25% yield). Compound 7 could be transformed into 8 in 76% yield by treating with the same reaction conditions again (total yield of 8: 82%). IR (ATR) v 3368, 3324, 3052, 3024, 2921, 2851, 1602, 1505, 1477, 744, 694 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 2.64—2.74 (m, 2H), 2.90 (dd, J=5.6, 11.6 Hz, 1H), 3.03—3.08 (m, 1H), 3.10 (dd, J=7.6, 11.6 Hz, 1H), 3.93 (dd, J=1.6, 12.8 Hz, 1H), 4.00 (d, J=12.8 Hz, 1H), 4.30-4.70 (broad peak (NH), 2H), 6.54-6.56 (m, 2H), 6.64—6.68 (m, 1H), 6.88—6.91 (m, 1H), 7.06—7.38 (m, 20H); <sup>13</sup>C-NMR  $(CDCl_2)$   $\delta$ : 39.2, 45.2, 49.8 (d, J=19.8 Hz), 57.9, 113.0 (2C), 116.9, 126.2, 127.4, 128.4—129.3 (m, 14C), 133.7 (d, J=9.8 Hz) (2C), 133.9 (d, J=9.8 Hz) (2C), 134.0, 135.9 (d, J=14.0 Hz), 136.8 (d, J=9.9 Hz), 136.9 (d, J=9.9 Hz), 138.8, 144.3 (d, J=23.8 Hz), 148.8; <sup>31</sup>P-NMR (CDCl<sub>3</sub>)  $\delta$ : -15.4; ESI-HR-MS. Calcd for C<sub>34</sub>H<sub>34</sub>N<sub>2</sub>P (M+H<sup>+</sup>): 501.2460. Found: 501.2453;  $[\alpha]_{\rm D}^{24}$  +3.55 (c=0.81, CHCl<sub>3</sub>).

Compound  $(S,R_p)$ -9a and  $(S,S_p)$ -9b To a stirred solution of 8 (721.1 mg, 1.44 mmol) and triethylamine (0.783 ml, 5.62 mmol) in toluene (14.4 ml) at -78 °C was added phosphorous trichloride (0.138 ml, 1.58 mmol) over 3 min. The reaction temperature was gradually warmed up to room temperature, and then the mixture was kept stirring for 12 h. After diluting with AcOEt, the reaction was quenched with the addition of water. The obtained mixture was washed with water, brine, and then dried over Na2SO4. After concentration in vacuo, the obtained residue was purified by flash column chromatography (SiO2, hexane/AcOEt=4/1 to 1/1) to give  $(S,R_p)$ -9a (213.1 mg, 27% yield) and  $(S,S_p)$ -9b (431.8 mg, 55% yield) as white solids. (S,R<sub>p</sub>)-9a: IR (ATR) v 3068, 2926, 1600, 1500, 1434, 1302, 1232, 1204, 1166, 1109, 1029, 963, 744, 695 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 2.44 (dd, J=10.0, 13.2 Hz, 1H), 3.13 (dd, J=3.6, 13.2 Hz, 1H), 3.24 (ddd, J=4.4 Hz (CH<sub>2</sub>-NPh-P(=O)H), 9.6, 9.6 Hz, 1H), 3.44 (ddd, J=6.0 Hz(CH<sub>2</sub>-NPh-P(=O)H), 6.0, 9.6 Hz, 1H), 3.68-3.78 (m, 1H), 4.38 (dd, J=9.6 Hz (H(O=)<u>P</u>-NC<u>H</u><sub>2</sub>Ar), 15.6 Hz, 1H), 4.90 (ddd, J=5.2 Hz $(Ph_2P-C-C-CH_2N)$ , 10.8 Hz  $(H(O=)P-NCH_2Ar)$ , 15.6 Hz, 1H), 6.87-7.08 (m, 7H), 7.20–7.52 (m, 16H), 7.58 (d, J=629.2 Hz (P(=O)H), 1H), 7.82– 7.85 (m, 1H); <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  $\delta$ : 39.4, 43.8 (dd, J=6.5, 27.5 Hz), 47.8 (d, J=9.5 Hz), 56.1 (d, J=6.9 Hz), 115.8 (d, J=5.3 Hz) (2C), 121.6, 126.8, 128.4—132.1 (m, 15C), 133.3, 133.7 (d, J=19.5 Hz) (2C), 134.1 (d, J=19.5 Hz) (2C), 135.8 (d, J=14.1 Hz), 136.0 (d, J=9.2 Hz), 136.8, 141.2 (dd, J=3.4, 23.6 Hz), 141.6 (d, J=7.3 Hz); <sup>31</sup>P-NMR (CDCl<sub>3</sub>)  $\delta$ : -16.3 (d, J=10.2 Hz), 12.4 (d, J=10.2 Hz); <sup>31</sup>P-NMR (CDCl<sub>3</sub>)  $\delta$ : -15.3, 11.3; ESI-HR-MS. Calcd for C<sub>34</sub>H<sub>32</sub>N<sub>2</sub>NaOP<sub>2</sub> (M+Na<sup>+</sup>): 569.1888. Found: 569.1900;  $[\alpha]_{D}^{24}$  -68.0 (c=0.41, CHCl<sub>3</sub>). (S,S<sub>P</sub>)-9b: IR (ATR) v 3051, 2926, 1600, 1497, 1473, 1434, 1301, 1228, 1166, 965, 742, 697 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ: 2.72—2.42 (m, 1H), 2.73 (dd, J=10.8, 13.2 Hz, 1H), 3.03—3.09 (m, 1H), 3.24—3.33 (m, 1H), 3.34 (dd, J=3.6, 13.2 Hz, 1H), 4.55 (dd, J=8.8 Hz  $(H(O=)\underline{P}-NC\underline{H}_{2}Ar)$ , 14.4 Hz, 1H), 4.79 (dd, J=6.8 Hz ( $H(O=)\underline{P}-NC\underline{H}_{2}Ar$ ), 14.4 Hz, 1H), 6.94-7.06 (m, 6H), 7.14-7.33 (m, 16H), 7.40-7.44 (m, 1H), 7.46 (d, J=628.8 Hz ( $\underline{P}(=O)\underline{H}$ ), 1H), 7.54–7.57 (m, 1H); <sup>13</sup>C-NMR

 $\begin{array}{l} ({\rm CDCl}_3) \; \delta:\; 38.4,\; 45.6 \; ({\rm dd},\; J{=}7.0,\; 20.5\,{\rm Hz}),\; 47.8 \; ({\rm d},\; J{=}9.2\,{\rm Hz}),\; 56.1 \; ({\rm d},\; J{=}6.5\,{\rm Hz}),\; 115.7 \; ({\rm d},\; J{=}5.3\,{\rm Hz})\; (2C),\; 121.6,\; 126.6,\; 128.4{---}129.3 \; ({\rm m},\; 9C),\\ 129.2 \; ({\rm d},\; J{=}5.4\,{\rm Hz})\; (2C),\; 129.2 \; ({\rm d},\; J{=}5.4\,{\rm Hz})\; (2C),\; 130.1 \; ({\rm d},\; J{=}5.4\,{\rm Hz}),\\ 133.5 \; ({\rm d},\; J{=}19.5\,{\rm Hz})\; (2C),\; 133.5 \; ({\rm d},\; J{=}19.5\,{\rm Hz})\; (2C),\; 135.1,\; 136.0 \; ({\rm d},\; J{=}8.8\,{\rm Hz}),\; 136.5 \; ({\rm d},\; J{=}3.1\,{\rm Hz}),\; 136.6 \; ({\rm d},\; J{=}9.1\,{\rm Hz}),\; 137.9,\; 141.2 \; ({\rm dd},\; J{=}6.1,\; 25.2\,{\rm Hz}),\; 141.9 \; ({\rm d},\; J{=}8.1\,{\rm Hz});\; {}^{31}{\rm P}{\rm -NMR}\; ({\rm CDCl}_3)\; \delta:\; -16.3 \; ({\rm d},\; J{=}10.2\,{\rm Hz}),\; 12.4 \; ({\rm d},\; J{=}10.2\,{\rm Hz});\; {\rm ESI-HR-MS}.\; {\rm Calcd}\; {\rm for}\; {\rm C}_{34}{\rm H}_{32}{\rm N}_{2}{\rm NaOP}_{2}\; ({\rm M}{+}{\rm Na}^+);\; 569.1888.\; {\rm Found}:\; 569.1892;\; [\alpha]_{2}^{23}+38.4\; (c{=}0.58,\; {\rm CHCl}_3). \end{array}$ 

General Procedure for the Pd-Catalyzed Asymmetric Allylic Alkylation Using (*S*,*S*<sub>p</sub>)-9b To a stirred solution of  $[\eta^3$ -C<sub>3</sub>H<sub>5</sub>PdCl]<sub>2</sub> (1.1 mg, 0.003 mmol), (*S*,*S*<sub>p</sub>)-9b (3.3 mg, 0.006 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 ml) at room temperature was added BSA (222 ml, 0.90 mmol). After being stirred for 10 min at the same temperature, a CH<sub>2</sub>Cl<sub>2</sub> solution of **11** (76.0 mg, 0.30 mmol in 0.5 ml of CH<sub>2</sub>Cl<sub>2</sub>) and dimethyl malonate (103 ml, 0.90 mmol) were added successively to the reaction at 4 °C. After 30 min, the reaction was concentrated under reduced pressure. The obtained residue was purified by flash column chromatography (SiO<sub>2</sub>, hexane/AcOEt, 30/1) to give (*R*)-**12**<sup>9</sup>) (96.3 mg, 99% yield, 93% ee) as colorless oil. The enantiomeric excess was determined by HPLC analysis (DAICEL CHIRALPAK AD-H, 2-propanol/hexane 8/92, flow rate 0.5 ml/min, *t*<sub>R</sub> 22.9 min [(*R*)-isomer] and 31.8 min [(*S*)-isomer], detection at 254 nm).

**Compound** (S)-13<sup>11)</sup> The enantiomeric excess was determined by HPLC analysis (DAICEL CHIRALCEL OJ-H, 2-propanol/hexane 15/85, flow rate 0.4 ml/min,  $t_R$  27.1 min [(S)-isomer] and 35.3 min [(R)-isomer], detection at 254 nm).

**Compound (5)-14**<sup>11)</sup> The enantiomeric excess was determined by HPLC analysis (DAICEL CHIRALCEL OJ-H, 2-propanol/hexane 5/95, flow rate 0.5 ml/min,  $t_{\rm R}$  20.5 min [(S)-isomer] and 29.1 min [(R)-isomer], detection at 254 nm).

Acknowledgments This work was supported in part by a Grant-in-Aid for Encouragement of Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

### **References and Notes**

- For a review of transition metal-catalyzed asymmetric allylic substitutions, see: Trost B. M., Van Vranken D. L., *Chem. Rev.*, 96, 395–422 (1996).
- For a review of transition metal-catalyzed asymmetric allylic substitutions, see: Trost B. M., Crawley M. L., *Chem. Rev.*, **103**, 2921–2943 (2003).
- For a review of transition metal-catalyzed asymmetric allylic substitutions, see: Lu Z., Ma S., Angew. Chem. Int. Ed., 47, 258–297 (2008).
- Hamada Y., Seto N., Ohmori H., Hatano K., *Tetrahedron Lett.*, 37, 7565—7568 (1996).
- Hamada Y., Seto N., Takayanagi Y., Nakano T., Hara O., *Tetrahedron Lett.*, 40, 7791–7794 (1999).
- Hamada Y., Sakaguchi K., Hatano K., Hara O., *Tetrahedron Lett.*, 42, 1297—1299 (2001).
- Hara O., Koshizawa T., Makino K., Kunimune I., Namiki A., Hamada Y., *Tetrahedron*, 63, 6170–6181 (2007).
- Nemoto T., Matsumoto T., Masuda T., Hitomi T., Hatano K., Hamada Y., J. Am. Chem. Soc., 126, 3690—3691 (2004).
- 9) Nemoto T., Masuda T., Matsumoto T., Hamada Y., J. Org. Chem., 70, 7172-7178 (2005).
- Nemoto T., Fukuda T., Matsumoto T., Hitomi T., Hamada Y., Adv. Synth. Catal., 347, 1504—1506 (2005).
- Nemoto T., Masuda T., Akimoto Y., Fukuyama T., Hamada Y., Org. Lett., 7, 4447–4450 (2005).
- 12) Nemoto T., Jin L., Nakamura H., Hamada Y., *Tetrahedron Lett.*, **47**, 6577–6581 (2006).
- Nemoto T., Sakamoto T., Matsumoto T., Hamada Y., *Tetrahedron Lett.*, 47, 8737–8740 (2006).
- 14) Nemoto T., Fukuyama T., Yamamoto E., Tamura S., Fukuda T., Matsumoto T., Akimoto Y., Hamada Y., Org. Lett., 9, 927–930 (2007).
- Nemoto T., Sakamoto T., Fukuyama T., Hamada Y., *Tetrahedron Lett.*, 48, 4977–4981 (2007).
- Nemoto T., Harada T., Matsumoto T., Hamada Y., *Tetrahedron Lett.*, 48, 6304–6307 (2007).
- 17) Jin L., Nemoto T., Nakamura H., Hamada Y., *Tetrahedron: Asymmetry*, 19, 1106–1113 (2008).
- Nemoto T., Tamura S., Sakamoto T., Hamada Y., *Tetrahedron: Asymmetry*, **19**, 1751–1759 (2008).
- 19) Nemoto T., Kanematsu M., Tamura S., Hamada Y., Adv. Synth. Catal.,

**351**, 1773—1778 (2009).

- 20) Nemoto T., Yamamoto E., Franzén R., Fukuyama T., Wu R., Fukamachi T., Kobayashi H., Hamada Y., Org. Lett., 12, 872–875 (2010).
- 21) For a review, see: Nemoto T., Hamada Y., Chem. Rec., 7, 150-158 (2007).
- 22) For a review, see: Nemoto T., Chem. Pharm. Bull., 56, 1213–1228 (2008).
- 23) Aspartic acid-derived P-chiral DIAPHOX preligands with  $(S,S_p)$  configurations are not accessible because of the characteristic reaction

pathway in the stage of introduction of the phosphine oxide moiety. See ref. 9 for details.

- 24) Breit B., Laungani A. C., Tetrahedron: Asymmetry, 14, 3823—3826 (2003).
- 25) The absolute configuration of the phosphorus atom of 9a and 9b was predicted by comparing the measured optical rotation with that of (S,R<sub>p</sub>)-(-)-10a and (S,S<sub>p</sub>)-(+)-10b.
- 26) The Pd-ligand ratio (Pd/10a or Pd/10b=1/2) was set based on the previous examinations using DIAPHOX 1. See ref. 9 for details.